Covalent binding of xenobiotics to specific proteins in the liver

Drug Metabolism Reviews

Volumn 29, Issue 1-2, 1997, Pages 39-57

  Pumford, Neil R ^a   Halmes, N Christine ^a   Hinson, Jack A ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; HALOTHANE; PARACETAMOL; TRICHLOROETHYLENE; XENOBIOTIC AGENT;

CONFERENCE PAPER; COVALENT BOND; DRUG METABOLISM; DRUG OVERDOSE; DRUG PROTEIN BINDING; IMMUNOCHEMISTRY; LIVER METABOLISM; LIVER TOXICITY; NONHUMAN; XENOBIOTIC METABOLISM;

EID: 0030788713     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.3109/03602539709037572     Document Type: Conference Paper

References (67)

1. L. R. Pohl, An immunochemical approach of identifying and characterizing protein targets of toxic reactive metabolites. Chem. Res. Toxicol., 6, 786-793 (1993).
2. D. W. Roberts, N. R. Pumford, D. W. Potter, R. W. Benson, and J. A. Hinson, A sensitive immunochemical assay for acetaminophen-protein adducts. J. Pharmacol. Exp. Ther., 241, 527-533 (1987).
3. A. M. Matthews, D. W. Roberts, J. A. Hinson, and N. R. Pumford, Acetaminophen-induced hepatotoxicity: Analysis of total covalent binding versus specific binding to cysteine, Drug Metab. Dispos., 24, 1192-1196 (1996).
4. N. R. Pumford, T. G. Myers, J. C. Davila, R. J. Highet, and L. R. Pohl, Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac, Chem. Res. Toxicol., 6, 147-150 (1993).
5. J. B. Bartolone, K. Sparks, S. D. Cohen, and E. A. Khairallah, Immunochemical detection of acetaminophen-bound liver proteins, Biochem. Pharmacol., 36, 1193-1196 (1987).
6. H. Satoh, Y. Fukuda, D. K. Anderson, V. J. Ferrans, J. R. Gillette, and L. R. Pohl, Immunological studies on the mechanism of halothane-induced hepatotoxicity: Immunohistochemical evidence of trifluoroacetylated hepatocytes. J. Pharmacol. Exp. Ther., 233, 857-862 (1985).
7. N. C. Halmes, D. C. McMillan, J. E. Oatis, Jr., and N. R. Pumford, Immunochemical detection of protein adducts in mice treated with trichloroethylene, Chem. Res. Toxicol., 9, 451-456 (1996).
8. D. W. Potter, N. R. Pumford, J. A. Hinson, R. W. Benson, and D. W. Roberts, Epitope characterization of acetaminophen bound to protein and nonprotein sulfhydryl groups by an enzyme-linked immunosorbent assay, J. Pharmacol. Exp. Ther., 248, 182-189 (1989).
9. N. R. Pumford, J. A. Hinson, D. W. Potter, K. L. Rowland, R. W. Benson, and D. W. Roberts, Immunochemical quantitation of 3-(cystein-S-yl)acetaminophen adducts in serum and liver proteins of acetaminophen-treated mice, J. Pharmacol. Exp. Ther., 248, 190-196 (1989).
10. N. R. Pumford, D. W. Roberts, R. W. Benson, and J. A. Hinson, Immunochemical quantitation of 3-(cystein-S-yl)acetaminophen protein adducts in subcellular liver fractions following a hepatotoxic dose of acetaminophen, Biochem. Pharmacol., 40, 573-579 (1990).
11. D. W. Roberts, T. J. Bucci, R. W. Benson, A. R. Warbritton, T. A. McRae, N. R. Pumford, and J. A. Hinson, Immunohistochemical localization and quantification of the 3-(cystein-5-yl)-acetaminophen protein adduct in acetaminophen hepatotoxicity, Am. J. Pathol., 138, 359-371 (1991).
12. J. B. Bartolone, S. D. Cohen, and E. A. Khairallah, Immunohistochemical localization of acetaminophen-bound liver proteins, Fundam. Appl. Toxicol, 13, 859-862 (1989).
13. S. J. Hargus, H. R. Amouzedeh, N. R. Pumford, T. G. Myers, S. C. McCoy, and L. R. Pohl, Metabolic activation and immunochemical localization of liver protein adducts of the nonsteroidal anti-inflammatory drug diclofenac, Chem. Res. Toxicol., 7, 575-582 (1994).
14. H. Satoh, J. R. Gillette, H. W. Davies, R. D. Schulick, and L. R. Pohl, Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats, Mol. Pharmacol., 28, 468-474 (1985).
15. N. R. Pumford, J. A. Hinson, R. W. Benson, and D. W. Roberts, Immunoblot analysis of protein containing 3-(cystein-S-yl)acetaminophen adducts in serum and subcellular liver fractions from acetaminophen-treated mice, Toxicol. Appl. Pharmacol., 104, 521-532 (1990).
16. J. R. Mitchell, D. J. Jollow, W. Z. Potter, D. C. Davis, J. R. Gillette, and B. B. Brodie, Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism., J. Pharmacol. Exp. Ther., 187, 185-194 (1973).
17. D. J. Jollow, J. R. Mitchell, W. Z. Potter, D. C. Davis, J. R. Gillette, and B. B. Brodie, Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo, J. Pharmacol. Exp. Ther., 187, 195-202 (1973).
18. J. B. Bartolone, R. B. Birge, K. Sparks, S. D. Cohen, and E. A. Khairallah, Immunochemical analysis of acetaminophen covalent binding to proteins: Partial characterization of the major acetaminophen-binding liver proteins, Biochem. Pharmacol., 37, 4763-4774 (1988).
19. N. R. Pumford, B. M. Martin and J. A. Hinson, A metabolite of acetaminophen covalently binds to the 56 kDa selenium binding protein, Biochem. Biophys. Res. Commun., 182, 1348-1355 (1992).
20. J. B. Bartolone, R. B. Birge, S. J. Bulera, M. K. Bruno, E. V. Nishanian, S. D. Cohen, and E. A. Khairallah, Purification, antibody production, and partial amino acid sequence of the 58-kDa acetaminophen-binding liver proteins, Toxicol. Appl. Pharmacol., 113, 19-29 (1992).
21. M. P. Bansal, T. Mukhopadhyay, J. Scott, R. G. Cook, R. Mukhopadhyay, and D. Medina, DNA sequencing of a mouse liver protein that binds selenium: Implications for selenium's mechanism of action in cancer prevention, Carcinogenesis, 11, 2071-2073 (1990).
22. J. Lanfear, J. Fleming, M. Walker, and P. Harrison, Different patterns of regulation of the genes encoding the closely related 56 kDa selenium- and acetaminophen-binding proteins in normal tissues and during carcinogenesis, Carcinogenesis, 14, 335-340 (1993).
23. N. R. Pumford, N. C. Halmes, B. M. Martin, R. J. Cook, C. Wagner, and J. A. Hinson, Covalent binding of acetaminophen to N-10-formyl-tetrahydrofolate dehydrogenase in mice, J. Pharmacol. Exp. Ther., 280, 501-505 (1997).
24. S. J. Bulera, R. B. Birge, S. D. Cohen, and E. A. Khairallah, Identification of the mouse liver 44-kDa acetaminophen-binding protein as a subunit of glutamine synthetase, Toxicol. Appl. Pharmacol., 134, 313-320 (1995).
25. M. Hong, S. D. Cohen, and E. A. Khairallah, Translocation of the major cytosolic acetaminophen (APAP) protein adducts into the nucleus, Toxicologist, 14, 427 (1994).
26. P. C. Burcham and A. W. Harman, Effect of acetaminophen hepatotoxicity on hepatic mitochondrial and microsomal calcium contents in mice, Toxicol. Lett., 44, 91-99 (1988).
27. P. C. Burcham and A. W. Harman, Mitochondrial dysfunction in paracetamol hepatotoxicity: In vitro studies in isolated mouse hepatocytes, Toxicol. Lett., 50, 37-48 (1990).
28. L. L. Meyers, W. P. Beierschmitt, E. A. Khairallah, and S. D. Cohen, Acetaminophen-induced inhibition of hepatic mitochondrial respiration in mice, Toxicol. Appl. Pharmacol., 93, 378-387 (1988).
29. W. M. Nazareth, J. K. Sethi, and A. E. McLean, Effect of paracetamol on mitochondrial membrane function in rat liver slices, Biochem. Pharmacol., 42, 931-936 (1991).
30. N. C. Halmes, J. A. Hinson, B. M. Martin, and N. R. Pumford, Glutamate dehydrogenase covalently binds to a reactive metabolite of acetaminophen, Chem. Res. Toxicol., 9, 541-546 (1996).
31. J. G. Kenna, J. Neuberger, and R. Williams, Evidence for expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis, Hepatology, 8, 1635-1641 (1988).
32. J. G. Kenna, J. Neuberger, and R. Williams, Identification by immunoblotting of three halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated hepatitis, J. Pharmacol. Exp. Ther., 242, 733-740 (1987).
33. J. G. Kenna, H. Satoh, D. D. Christ, and L. R. Pohl, Metabolic basis for a drug hypersensitivity: Antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane, J. Pharmacol. Exp. Ther., 245, 1103-1109 (1988).
34. L. R. Pohl, D. Thomassen, N. R. Pumford, L. E. Butler, H. Satoh, V. J. Ferrans, A. Perrone, B. M. Martin, and J. L. Martin. Hapten carrier conjugates associated with halothane hepatitis, Adv. Exp. Med. Biol., 283, 111-120 (1990).
35. L. R. Pohl, N. R. Pumford, and J. L. Martin, Mechanisms, chemical structures, and drug metabolism, Eur. J. Haematol., 57 (Suppl), 98-104 (1996).
36. H. R. Amouzadeh and L. R. Pohl, Processing of endoplasmic reticulum luminal antigens associated with halothane hepatitis in rat hepatocytes, Hepatology, 22, 936-943 (1995).
37. A. P. Brown and A. J. Gandolfi, Glutathione-S-transferase is a target for covalent modification by a halothane reactive intermediate in the guinea pig liver, Toxicology, 89, 35-47 (1994).
38. D. Schapira, L. Bassan, A. M. Nahir, and Y. Scharf, Diclofenac-induced hepatotoxicity, Postgrad. Med. J., 62, 63-65 (1986).
39. R. W. Sallie, T. McKenzie, W. D. Reed, M. F. Quinlan, and K. B. Shilkin, Diclofenac hepatitis, Austr. N. Z. J. Med., 21, 251-255 (1991).
40. E. G. Breen, J. McNicholl, E. Cosgrove, J. McCabe, and F. M. Stevens, Fatal hepatitis associated with diclofenac, Gut, 27, 1390-1393 (1986).
41. A. A. Dunk, R. P. Walt, W. J. Jenkins, and S. S. Sherlock, Diclofenac hepatitis, Br. Med. J., 284, 1605-1606 (1982).
42. S. M. Helfgott, C. J. Sandberg, D. Zakim, and J. Nestler, Diclofenac-associated hepatotoxicity, JAMA, 264, 2660-2662 (1990).
43. P. Purcell, D. Henry, and G. Melville, Diclofenac hepatitis, Gut, 32, 1381-1385 (1991).
44. T. J. Iveson, N. G. Ryley, P. M. Kelly, J. M. Trowell, J. O. McGee, and R. W. Chapman, Diclofenac associated hepatitis, J. Hepatol., 10, 85-89 (1990).
45. S. J. Hargus, B. M. Martin, J. W. George, and L. R. Pohl, Covalent modification of rat liver dipeptidyl peptidase IV (CD26) by the nonsteroidal anti-inflammatory drug diclofenac, Chem. Res. Toxicol., 8, 993-996 (1995).
46. J. V. Bruckner, B. D. Davis, and J. N. Blancato, Metabolism, toxicity, and carcinogenicity of trichloroethylene, Crit. Rev. Toxicol., 20, 31-50 (1989).
47. I. W. Davidson and R. P. Beliles, Consideration of the target organ toxicity of trichloroethylene in terms of metabolite toxicity and pharmacokinetics, Drug Metab. Rev., 23, 493-599 (1991).
48. E. M. Saihan, J. L. Burton, and K. W. Heaton, A new syndrome with pigmentation, scleroderma, gynaecomastia, Raynaud's phenomenon and peripheral neuropathy, Br. J. Dermatol., 99, 437-440 (1978).
49. U. F. Haustein and V. Ziegler, Environmentally induced systemic sclerosis-like disorders, Int. J. Dermatol., 24, 147-151 (1985).
50. J. E. Lockey, C. R. Kelly, G. W. Cannon, T. V. Colby, V. Aldrich, and G. K. Livingston, Progressive systemic sclerosis associated with exposure to trichloroethylene, J. Occup. Med., 29, 493-496 (1987).
51. K. H. Kilburn and R. H. Warshaw, Prevalence of symptoms of systemic lupus erythematosus (SLE) and of fluorescent antinuclear antibodies associated with chronic exposure to trichloroethylene and other chemicals in well water, Environ. Res., 57, 1-9 (1992).
52. T. Green, Chloroethylenes: A mechanistic approach to human risk evaluation, Annu. Rev. Pharmacol., 30, 73-89 (1990).
53. A. R. Goeptar, J. N. M. Commandeur, B. van Ommen, P. J. van Bladeren, and N. P. E. Vermeulen, Metabolism and kinetics of trichloroethylene in relation to toxicity and carcinogenicity: Relevance of the mercapturic acid pathway, Chem. Res. Toxicol., 8, 3-21 (1995).
54. N. C. Halmes, E. J. Perkins, D. C. McMillan, and N. R. Pumford, Detection of trichloroethylene-protein adducts in rat liver and plasma, submitted for publication 1996.
55. J. S. Landin, S. D. Cohen, and E. A. Khairallah, Identification of a 54-kDa mitochondrial acetaminophen-binding protein as aldehyde dehydrogenase, Toxicol. Appl. Pharmacol., 141, 299-307 (1996).
56. J. L. Martin, J. G. Kenna, B. M. Martin, D. Thomassen, G. F. Reed, and L. R. Pohl, Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase, Hepatology, 18, 858-863 (1993).
57. J. L. Martin, N. R. Pumford, A. C. LaRosa, B. M. Martin, H. M. Gonzaga, M. A. Beaven, and L. R. Pohl, A metabolite of halothane covalently binds to an endoplasmic reticulum protein that is highly homologous to phosphatidylinositol-specific phospholipase C-alpha but has no activity, Biochem. Biophys. Res. Commun., 178, 679-683 (1991).
58. M. Bourdi, D. Demady, J. L. Martin, S. K. Jabbour, B. M. Martin, J. W. George, and L. R. Pohl, cDNA cloning and baculovirus expression of the human liver endoplasmic reticulum P58: Characterization as a protein disulfide isomerase isoform, but not as a protease or a carnitine acyltransferase, Arch. Biochem. Biophys., 323, 397-403 (1995).
59. H. Satoh, B. M. Martin, A. H. Schulick, D. D. Christ, J. G. Kenna, and L. R. Pohl, Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase, Proc. Natl. Acad. Sci. USA, 86, 322-326 (1989).
60. L. E. Butler, D. Thomassen, J. L. Martin, B. M. Martin, J. G. Kenna, and L. R. Pohl, The calcium-binding protein calreticulin is covalently modified in rat liver by a reactive metabolite of the inhalation anesthetic halothane, Chem. Res. Toxicol., 5, 406-410 (1992).
61. N. R. Pumford, B. M. Martin, D. Thomassen, J. A. Burris, J. G. Kenna, J. L. Martin, and L. R. Pohl, Serum antibodies from halothane hepatitis patients react with the rat endoplasmic reticulum protein ERp72, Chem. Res. Toxicol., 6, 609-615 (1993).
62. J. C. Davila, N. R. Pumford, B. M. Martin, D. Thomassen, J. L. Martin, and L. R. Pohl, A trifluoroacetylated 82 kDa stress protein appears to be a neoantigen associated with halothane hepatitis, Toxicologist, 11, 268 (1991).
63. D. Thomassen, B. M. Martin, J. L. Martin, N. R. Pumford, and L. R. Pohl, Characterization of a halothane induced trifluoroacetylated 100 kDa neoantigen that is related to a glucose-regulated protein, FASEB J., 4, A599 (1990).
64. H. R. Amouzadeh, M. Bourdi, J. L. Martin, B. M. Martin, and L. R. Pohl, UDP-glucose:gylcoprotein glucosyltransferase associates with endoplasmic reticulum chaperons and its activity is decreased in vivo by the inhalation anesthetic halothane, Chem. Res. Toxicol., 10, 59-63 (1997).
65. E. Eliasson and J. G. Kenna, Cytochrome P450 2E1 is a cell surface autoantigen in halothane, Mol. Pharmacol., 50, 573-582 (1996).
66. M. Bourdi, W. Chen, R. M. Peter, J. L. Martin, J. T. M. Buters, S. D. Nelson, and L. R. Pohl, Human P4502E1 is a major autoantigen associated with halothane hepatitis and the epitopes are conformational, Chem. Res. Toxicol., 9, 1159-1166 (1996).
67. A. P. Brown, K. L. Hastings, A. J. Gandolfi, D. C. Liebler, and K. Brendel, Formation and identification of protein adducts to cytosolic proteins in guinea pig liver slices exposed to halothane, Toxicology, 73, 281-295 (1992).